{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:57:24Z","timestamp":1793750244263,"version":"4.6.1"},"reference-count":28,"publisher":"American Society of Hematology","issue":"11","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Neutropenia and neutrophil dysfunction in glycogen storage disease type 1b (GSD1b) are caused by the accumulation of 1,5-anhydroglucitol-6-phosphate in granulocytes. The antidiabetic drug empagliflozin reduces the concentration of 1,5-anhydroglucitol (1,5-AG), thus restoring neutrophil counts and functions, leading to promising results in previous case reports. Here, we present a comprehensive analysis of neutrophil function in 7 patients with GSD1b and 11 healthy donors, aiming to evaluate the immediate (after 3\u00a0months) and long-term (after 12\u00a0months) efficacy of empagliflozin compared with the reference treatment with granulocyte-colony stimulating factor (G-CSF). We found that most patients receiving G-CSF remained neutropenic with dysfunctional granulocytes, whereas treatment with empagliflozin increased neutrophil counts and improved functionality by inhibiting apoptosis, restoring phagocytosis and the chemotactic response, normalizing the oxidative burst, and stabilizing cellular and plasma levels of defensins and lactotransferrin. These improvements correlated with the decrease in serum 1,5-AG levels. However, neither G-CSF nor empagliflozin overcame deficiencies in the production of cathelicidin\/LL-37 and neutrophil extracellular traps. Given the general improvement promoted by empagliflozin treatment, patients were less susceptible to severe infections. G-CSF injections were therefore discontinued in 6 patients (and the dose was reduced in the seventh) without adverse effects. Our systematic analysis, the most extensive reported thus far, has demonstrated the superior efficacy of empagliflozin compared with G-CSF, restoring the neutrophil population and normal immune functions. This trial was registered as EudraCT 2021-000580-78.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012403","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T21:00:06Z","timestamp":1711486806000},"page":"2790-2802","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1269-5084","authenticated-orcid":false,"given":"Magdalena","family":"Kaczor","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Nutrition and Metabolic Diseases, Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8778-9259","authenticated-orcid":false,"given":"Stanislaw","family":"Malicki","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnologies, Jagiellonian University, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-5429","authenticated-orcid":false,"given":"Justyna","family":"Folkert","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnologies, Jagiellonian University, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0151-9723","authenticated-orcid":false,"given":"Ewelina","family":"Dobosz","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnologies, Jagiellonian University, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3221-9632","authenticated-orcid":false,"given":"Danuta","family":"Bryzek","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnologies, Jagiellonian University, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Chruscicka-Smaga","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnologies, Jagiellonian University, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-9927","authenticated-orcid":false,"given":"Milena","family":"Greczan","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Nutrition and Metabolic Diseases, Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0274-1278","authenticated-orcid":false,"given":"Dorota","family":"Wes\u00f3\u0142- Kucharska","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Nutrition and Metabolic Diseases, Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8949-047X","authenticated-orcid":false,"given":"Barbara","family":"Pi\u0105tosa","sequence":"additional","affiliation":[{"name":"3Histocompatibility Laboratory, Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Samborowska","sequence":"additional","affiliation":[{"name":"4Inborn Errors of Metabolism Laboratory, Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-0194","authenticated-orcid":false,"given":"Joanna","family":"Madzio","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics, Oncology & Hematology, Medical University of \u0141\u00f3d\u017a, \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9136-2722","authenticated-orcid":false,"given":"Janusz","family":"Ksi\u0105\u017cyk","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Nutrition and Metabolic Diseases, Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Ehmke vel Emczy\u0144ska","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Nutrition and Metabolic Diseases, Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Hajdacka","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Nutrition and Metabolic Diseases, Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Potempa","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnologies, Jagiellonian University, Krakow, Poland"},{"name":"6Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, Louisville, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"M\u0142ynarski","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics, Oncology & Hematology, Medical University of \u0141\u00f3d\u017a, \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9736-2838","authenticated-orcid":false,"given":"Dariusz","family":"Rokicki","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Nutrition and Metabolic Diseases, Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1248-2396","authenticated-orcid":false,"given":"Florian","family":"Veillard","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnologies, Jagiellonian University, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"issue":"3","key":"2024061015554050100_bib1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10545-014-9772-x","article-title":"Type I glycogen storage diseases: disorders of the glucose-6-phosphatase\/glucose-6-phosphate transporter complexes","volume":"38","author":"Chou","year":"2015","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"4","key":"2024061015554050100_bib2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1086\/302068","article-title":"A\u00a0gene on chromosome 11q23 coding for a putative glucose- 6-phosphate translocase is mutated in glycogen-storage disease types Ib and Ic","volume":"63","author":"Veiga-da-Cunha","year":"1998","journal-title":"Am J Hum Genet"},{"key":"2024061015554050100_bib3","doi-asserted-by":"crossref","first-page":"1145111","DOI":"10.3389\/fendo.2023.1145111","article-title":"Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders","volume":"14","author":"Maiorana","year":"2023","journal-title":"Front Endocrinol"},{"issue":"11","key":"2024061015554050100_bib4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1038\/gim.2014.128","article-title":"Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of medical genetics and genomics","volume":"16","author":"Kishnani","year":"2014","journal-title":"Genet Med"},{"issue":"5","key":"2024061015554050100_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10545-016-9932-2","article-title":"Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome","volume":"39","author":"Sentner","year":"2016","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"2","key":"2024061015554050100_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1067\/mpd.2000.105232","article-title":"Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European study on glycogen storage disease type I","volume":"137","author":"Visser","year":"2000","journal-title":"J\u00a0Pediatr"},{"issue":"suppl 1","key":"2024061015554050100_bib7","first-page":"S120","article-title":"Consensus guidelines for management of glycogen storage disease type 1b - European study on glycogen storage disease type 1","volume":"161","author":"Visser","year":"2002","journal-title":"Eur J Pediatr"},{"issue":"9","key":"2024061015554050100_bib8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood.2019004465","article-title":"Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor","volume":"136","author":"Wortmann","year":"2020","journal-title":"Blood"},{"issue":"25","key":"2024061015554050100_bib9","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM199206183262504","article-title":"Brief report: treatment of chronic inflammatory bowel disease in glycogen storage disease type Ib with colony-stimulating factors","volume":"326","author":"Roe","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024061015554050100_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/MOH.0000000000000474","article-title":"Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor","volume":"26","author":"Dale","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"2024061015554050100_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/08880018.2018.1440675","article-title":"Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length","volume":"35","author":"Li","year":"2018","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"2024061015554050100_bib12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1172\/JCI110647","article-title":"Energy metabolism of human neutrophils during phagocytosis","volume":"70","author":"Borregaard","year":"1982","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"2024061015554050100_bib13","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1182\/blood-2002-10-3128","article-title":"Apoptotic neutrophils in the circulation of patients with glycogen storage disease type 1b (GSD1b)","volume":"101","author":"Kuijpers","year":"2003","journal-title":"Blood"},{"issue":"18","key":"2024061015554050100_bib14","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2013-05-502435","article-title":"Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib","volume":"123","author":"Jun","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2024061015554050100_bib15","first-page":"691","article-title":"Infectious and bleeding complications in patients with glycogenosis Ib","volume":"139","author":"Ambruso","year":"1985","journal-title":"Am J Dis Child"},{"issue":"10","key":"2024061015554050100_bib16","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"issue":"7","key":"2024061015554050100_bib17","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2337\/db17-0100","article-title":"Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes","volume":"66","author":"Al-Jobori","year":"2017","journal-title":"Diabetes"},{"issue":"8","key":"2024061015554050100_bib18","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.gim.2022.04.001","article-title":"Efficacy and safety of empagliflozin in glycogen storage disease type Ib: data from an international questionnaire","volume":"24","author":"Gr\u00fcnert","year":"2022","journal-title":"Genet Med"},{"issue":"4","key":"2024061015554050100_bib19","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1097\/PG9.0000000000000356","article-title":"Clinical remission of severe Crohn\u2019s disease with empagliflozin monotherapy in a pediatric patient with glycogen storage disease type 1b","volume":"4","author":"Collen","year":"2023","journal-title":"JPGN Rep"},{"key":"2024061015554050100_bib20","doi-asserted-by":"crossref","first-page":"17562848231202138","DOI":"10.1177\/17562848231202138","article-title":"Crohn-like disease long remission in a pediatric patient with glycogen storage disease type Ib treated with empagliflozin: a case report","volume":"16","author":"Calia","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"2024061015554050100_bib21","doi-asserted-by":"crossref","first-page":"e1007773","DOI":"10.1371\/journal.ppat.1007773","article-title":"Triggering NETosis via protease-activated receptor (PAR)-2 signaling as a mechanism of hijacking neutrophils function for pathogen benefits","volume":"15","author":"Bryzek","year":"2019","journal-title":"PLoS Pathog"},{"issue":"2","key":"2024061015554050100_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1128\/cdli.2.2.227-232.1995","article-title":"Rapid whole-blood flow cytometry assay for diagnosis of chronic granulomatous disease","volume":"2","author":"O\u2019Gorman","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"issue":"7","key":"2024061015554050100_bib23","first-page":"e27264","article-title":"Repurposing of empagliflozin as a possible treatment for neutropenia and inflammatory bowel disease in glycogen storage disease type Ib: a case report","volume":"14","author":"Makrilakis","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"2024061015554050100_bib24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13023-020-01503-8","article-title":"Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib","volume":"15","author":"Gr\u00fcnert","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2024061015554050100_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13052-021-01100-w","article-title":"Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report","volume":"47","author":"Rossi","year":"2021","journal-title":"Ital J Pediatr"},{"issue":"11","key":"2024061015554050100_bib26","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/ped.14629","article-title":"Empagliflozin ameliorated neutropenia in a girl with glycogen storage disease Ib","volume":"63","author":"Mikami","year":"2021","journal-title":"Pediatr Int"},{"issue":"1","key":"2024061015554050100_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13023-022-02345-2","article-title":"Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre","volume":"17","author":"Halligan","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2024061015554050100_bib28","doi-asserted-by":"crossref","first-page":"1071464","DOI":"10.3389\/fped.2022.1071464","article-title":"Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients","volume":"10","author":"Hexner-Erlichman","year":"2022","journal-title":"Front Pediatr"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2790\/2228384\/blooda_adv-2023-012403-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2790\/2228384\/blooda_adv-2023-012403-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T15:56:06Z","timestamp":1718034966000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/11\/2790\/515503\/Neutrophil-functions-in-patients-with-neutropenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012403","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]}}}